Literature DB >> 28447352

Dermoscopic evaluation of melanonychia.

Hiroshi Koga1.   

Abstract

The prevalence of melanonychia is approximately 1%, and it is a common symptom encountered in daily practise. However, it may also be the first symptom of melanoma of the nail apparatus. Evaluation of adult melanonychia with clinical information and clinical images is sometimes difficult for clinicians. Dermoscopic observation provides important information based on the algorithm method. Melanonychia in children requires a different approach, because dermoscopic features observed in adult nail apparatus melanoma are generally observed in benign pediatric cases.
© 2017 Japanese Dermatological Association.

Entities:  

Keywords:  dermoscopy; longitudinal melanonychia; nail apparatus melanoma; nail apparatus nevus; pseudo-Hutchinson's sign

Mesh:

Year:  2017        PMID: 28447352     DOI: 10.1111/1346-8138.13863

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  4 in total

1.  Dermoscopic Evaluation of Longitudinal Melanonychia in Children: A Prospective Study.

Authors:  Mahshid Sadat Ansari; Hamidreza Mahmoudi; Ali Sadeghinia; Shadi Azizzadeh-Roodpishi; Alireza Ghanadan; Maryam Daneshpazhooh
Journal:  Indian J Dermatol       Date:  2021 Jul-Aug       Impact factor: 1.494

2.  Longitudinal melanonychia in childhood: a great challenge.

Authors:  Isabela Boechat Morato; João Renato Vianna Gontijo; Glaysson Tassara Tavares; Flávia Vasques Bittencourt
Journal:  An Bras Dermatol       Date:  2022-06-09       Impact factor: 2.113

Review 3.  Acral Melanocytic Neoplasms: A Comprehensive Review of Acral Nevus and Acral Melanoma in Asian Perspective.

Authors:  Sanghyun Park; Sook-Jung Yun
Journal:  Dermatopathology (Basel)       Date:  2022-08-19

4.  Melanonychia associated with subungual follicular inclusions: report of three cases.

Authors:  Marina Câmara de Oliveira; Carlos Baptista Barcaui; Elisa de Oliveira Barcaui; Juan Piñeiro-Maceira
Journal:  An Bras Dermatol       Date:  2020-02-12       Impact factor: 1.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.